Currently, estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative status in breast cancer patients is the only used predictive biomarker for response to CDK4/6 inhibition [39, 40]. This evidence concerns the gene ESR1 and breast carcinoma.